Effects of cell therapy with mesenchymal stem cells and platelet-rich plasma in the treatment of knee osteoarthritis
Not Applicable
- Conditions
- Osteoarthritis, Knee
- Registration Number
- RBR-2fr526n
- Lead Sponsor
- niversidade Federal de Mato Grosso do Sul
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Data analysis completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Volunteer individuals were included; diagnosed through physical assessment; be classified by imaging with osteoarthritis grade II to IV; who already had an indication for knee surgery; patients unresponsive to conservative treatment (physical and drug) commonly used in the Unified Health System (SUS) for at least 6 months.
Exclusion Criteria
Individuals with extreme deformities of the knee joint were excluded; who reported having hemophilia, anemia, gastrointestinal diseases, cancer, thyroid, liver, and previous nephrological disorders and HIV; patients who were chronically using immunosuppressive and anticoagulant drugs.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The use of mesenchymal stem cells in conjunction with platelet-rich plasma for the treatment of osteoarthritis is the most effective intervention when compared to the currently proposed conventional surgical treatment. Joint inflammation was assessed by analyzing the synovial fluid of the treated joint, collection took place before surgery and after 6 months of cell application. Analysis was performed by flow cytometry with an inflammatory cytokine marker kit.
- Secondary Outcome Measures
Name Time Method The group that used the combination of mesenchymal stem cells and platelet-rich plasma in the treatment of osteoarthritis was the most effective in terms of reducing inflammatory cytokines and improving the quality of synovial fluid in the treated joint. Decreases of 40% in the cytokine IL 1b, 72% in IL 6, 50% in IL 8, 20% in IL 10, 29% in IL 12p70 and 46% in TNF were observed when compared to the initial state of treatment.